Context Therapeutics Inc. — FY2022 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2022. Context Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its lead program, CTIM-76, is a preclinical CLDN6xCD3 bispecific antibody; no clinical studies of CTIM-76 had begun by the filing date. The company had no approved products or product-sales revenue.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $7.1 million | $3.8 million |
| General and administrative expense | $7.8 million | $3.6 million |
| Operating loss | $15.4 million | $10.5 million |
| Net loss | $14.8 million | $10.5 million |
| Net loss per share, basic and diluted | $0.93 | $3.69 |
| Cash used in operating activities | $13.5 million | $8.8 million |
| Cash and cash equivalents at year-end | $35.5 million | $49.6 million |
| Total assets | $38.0 million | $51.3 million |
| Total liabilities | $3.2 million | $3.0 million |
Gross margin and operating margin are not meaningful because the company reported no revenue. Year-end current assets were $37.9 million and current liabilities were $3.2 million. The balance sheet shows no borrowings at December 31, 2022; liabilities principally comprised accounts payable, accruals and lease obligations. The accumulated deficit was $44.1 million. The company reported no income tax expense and recorded a full valuation allowance against deferred tax assets.
Changes versus prior year
Net loss increased 42% year over year. R&D expense rose 86%, mainly from higher ONA-XR manufacturing and clinical-trial costs, including initiation of the ELONA study, and additional CTIM-76 work. G&A expense rose 114%, reflecting higher compensation and stock-based compensation, insurance costs, and public-company expenses. Operating cash use increased by $4.7 million. Cash fell $14.2 million during 2022; financing activities used $0.1 million, compared with $58.4 million provided in 2021, when the company completed its IPO and a private placement.
Outlook, management commentary and key risks
- On March 22, 2023, after year-end, the company announced it would discontinue ONA-XR development, wind down related trials and explore strategic options for the program, while prioritizing CTIM-76. The OATH Phase 2 trial had identified elevated liver function tests in three patients; one discontinued treatment, and none of the elevations was considered a serious adverse event. Management cited likely additional costs and delays to analyze and address the findings, as well as a more competitive breast-cancer treatment landscape.
- Management estimated that $35.5 million of year-end cash would fund operations into late 2024 following the portfolio shift. This is a forward-looking estimate based on assumptions; the filing cautions that available capital could be used sooner. The company expects to need additional capital and has no credit facility or committed financing source.
- CTIM-76 IND-enabling studies were underway; the company expected to submit an IND to support human trials in the first quarter of 2024. The program remains preclinical, and the timeline and financing needs are uncertain.
- Material risks include clinical and regulatory failure, need for additional financing and potential dilution, reliance on third-party manufacturers and research organizations, intellectual-property and licensing risks, and possible disputes during the ONA-XR wind-down. CTIM-76 also faces competition from other CLDN6 programs.
- Nasdaq notified the company in January 2023 that its share price had failed the $1 minimum bid-price requirement for 30 consecutive business days; the initial compliance period ran through July 24, 2023. Failure to regain compliance could lead to delisting.
- The company reported effective disclosure controls and effective internal control over financial reporting as of December 31, 2022. Its auditor gave an unqualified opinion on the financial statements but did not attest to internal-control effectiveness, consistent with the company’s emerging-growth-company exemption.
Important facts for investors to verify
- Current cash balance, actual operating burn and whether management’s late-2024 runway estimate remains valid after discontinuing ONA-XR.
- Progress, costs and regulatory status of CTIM-76 IND-enabling work and the expected first-quarter 2024 IND filing.
- Status and terms of any sale, licensing or other strategic transaction for ONA-XR, including trial wind-down obligations and potential counterparty disputes.
- Any new financing, dilution, partnership or licensing arrangements, and the remaining milestone and royalty obligations under the Integral agreement.
- Nasdaq listing compliance and any subsequent developments affecting the share price or listing status.